指南与共识胸部肿瘤头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

ESMO 关于日常实践与临床研究中检测 RET 融合和突变的标准方法推荐

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
指南 / 共识 · Ann Oncol · 2021-01-14

ESMO 转化研究与精准医学工作组针对 RET 基因融合与突变的检测方法开展综述并给出推荐。文章回顾了多激酶抑制剂与选择性 RET 抑制剂(普拉替尼、塞尔帕替尼)在 RET 异常肿瘤中的表现,并提出日常临床检测可靶向 RET 重排与突变的合理路径。

要点

  • RET 异常是多类实体瘤的生长驱动因素,需在临床中识别可靶向的 RET 融合与突变。
  • 选择性 RET 抑制剂在 RET 异常肿瘤中显示显著且持久的抗肿瘤活性与可控毒性。
  • ESMO 工作组推荐了日常临床检测 RET 重排与突变的标准化方法路径。

核心结论

  • ESMO 转化研究与精准医学工作组提出日常临床检测可靶向 RET 重排与突变的推荐方法。

研究设计与样本

  • ESMO 转化研究与精准医学工作组发起协作项目,综述 RET 基因异常的现有检测方法、潜在应用及合理检测路径。

主要发现

  • 多激酶抑制剂在 RET 异常肿瘤中抗 RET 活性结果不一,且靶点特异性低导致副作用与脱靶毒性增加,常需减量或停药。
  • 选择性 RET 抑制剂普拉替尼与塞尔帕替尼在临床试验中显示显著且持久的抗肿瘤活性及可控毒性。
  • 塞尔帕替尼近期获美国食品药品监督管理局批准。

临床怎么用

  • 在临床实践中应按 ESMO 推荐路径对实体瘤进行 RET 融合基因与突变的常规检测,以识别可靶向 RET 异常的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant activation of RET is a critical driver of growth and proliferation in diverse solid tumours. Multikinase inhibitors (MKIs) showing anti-RET activities have been tested in RET-altered tumours with variable results. The low target specificity with consequent increase in side-effects and off-target toxicities resulting in dose reduction and drug discontinuation are some of the major issues with MKIs. To overcome these issues, new selective RET inhibitors such as pralsetinib (BLU-667) and selpercatinib (LOXO-292) have been developed in clinical trials, with selpercatinib recently approved by the Food and Drug Administration (FDA). The results of these trials showed marked and durable antitumour activity and manageable toxicity profiles in patients with RET-altered tumours. The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods for the detection of RET gene alterations, their potential applications and strategies for the implementation of a rational approach for the detection of RET fusion genes and mutations in human malignancies. We present here recommendations for the routine clinical detection of targetable RET rearrangements and mutations.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Belli C, Penault-Llorca F, Ladanyi M, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol. 2021. PMID: 33455880. doi:10.1016/j.annonc.2020.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。